What is the 13F Pro Quality Score for EMBC?

13F Pro ranks Embecta Corp. (EMBC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EMBC's current score at https://13fpro.ai/research/EMBC (free sign-up required for the full ranking).

Where does 13F Pro source EMBC data?

All Embecta Corp. fundamentals and ownership data come directly from SEC EDGAR. Embecta Corp. files with the SEC under CIK 1872789. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EMBC in?

Embecta Corp. (EMBC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EMBC research updated on 13F Pro?

EMBC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Embecta Corp.(EMBC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1872789 EMBC stock profile & AI dashboard →

13F Pro Quality Score

60.2/100

Rank #869 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

20.5/100

Profitability

77.2/100

Balance Sheet

86.4/100

Earnings Quality

67.9/100

Free Cash Flow

73.2/100

Institutional Flow

82.3/100

Revenue Scale

50.1/100

Dilution Risk

34.2/100

EMBC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Embecta Corp. (EMBC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EMBC at 60.2/100 on a 32-signal composite quality model, placing it at rank #869 of 2,879 stocks — the top half of the AI-ranked universe. EMBC scores in the top quartile across balance sheet strength (86.4), institutional flow (82.3), profitability (77.2). Areas of concern include revenue growth (20.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 34.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Embecta Corp. reports quarterly revenue of $221.8M, net income of $-4.1M, free cash flow of $30.6M. Top institutional holders of EMBC by reported 13-F value include BlackRock,, YACKTMAN ASSET MANAGEMENT, River Road Asset Management,, based on the most recent SEC filings. EMBC trades on the Nasdaq exchange and files with the SEC under CIK 1872789. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EMBC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Embecta Corp. directly from SEC EDGAR. Embecta Corp.'s 13F Pro composite quality score has ranged between 8 and 64 since 2022, currently 60.2 — a declining long-term trajectory across 49 quarterly and live scoring snapshots.

✦

Fun facts about Embecta Corp.

Quirks, history, and lore behind EMBC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the range of roughly $1 billion, serving a global customer base across more than 100 countries — not flashy, but very steady demand.
3
The History
Spun off from a major medical conglomerate in 2022, it became an independent public company after decades of operating quietly inside a much larger parent.
4
The Secret
Its entire business revolves around a single delivery mechanism used by hundreds of millions of people every day to manage a chronic metabolic condition.
5
The Lore
The parent it was carved out of? BD (Becton, Dickinson) — and this spinoff inherited the world's leading franchise in insulin delivery devices, including syringes and pen needles.
6
The Giveaway
If you have diabetes and inject insulin, there's a good chance the pen needle or syringe in your hand was made by this company — the pure-play spinoff BD created just for that.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$221.8M

Net Income

Q2 2026

$-4.1M

Free Cash Flow

Q2 2026

$30.6M

ROIC

Q2 2026

5.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.8% YoY

$1.08BFY 2025

FY22 $1.13BFY23 $1.12BFY24 $1.12BFY25 $1.08B

Net Income

+21.8% YoY

$95.4MFY 2025

FY22 $223.6MFY23 $70.4MFY24 $78.3MFY25 $95.4M

Operating Income

+45.1% YoY

$242.1MFY 2025

FY22 $309.6MFY23 $221.5MFY24 $166.8MFY25 $242.1M

EPS (Diluted)

+20.9% YoY

$1.62FY 2025

FY22 $3.89FY23 $1.22FY24 $1.34FY25 $1.62

Total Assets

-15.1% YoY

$1.09BFY 2025

FY22 $1.09BFY23 $1.21BFY24 $1.29BFY25 $1.09B

Total Debt

-11.1% YoY

$1.41BFY 2025

FY22 $1.61BFY23 $1.60BFY24 $1.58BFY25 $1.41B

Op. Cash Flow

+437.0% YoY

$191.7MFY 2025

FY22 $412.2MFY23 $67.7MFY24 $35.7MFY25 $191.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$1.08B -3.8%	$1.12B +0.2%	$1.12B -0.8%	$1.13B -3.1%	$1.17B	—
Net Income	$95.4M +21.8%	$78.3M +11.2%	$70.4M -68.5%	$223.6M -46.1%	$414.8M	—
Operating Income	$242.1M +45.1%	$166.8M -24.7%	$221.5M -28.5%	$309.6M -37.1%	$492.0M	—
EPS (Diluted)	$1.62 +20.9%	$1.34 +9.8%	$1.22 -68.6%	$3.89 -46.6%	$7.28	—
Total Assets	$1.09B -15.1%	$1.29B +5.8%	$1.21B +11.8%	$1.09B +37.9%	$788.0M	—
Total Debt	$1.41B -11.1%	$1.58B -1.2%	$1.60B -0.3%	$1.61B	$0.00	—
Operating Cash Flow	$191.7M +437.0%	$35.7M -47.3%	$67.7M -83.6%	$412.2M -9.7%	$456.3M	—

Get alerted when EMBC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Embecta Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EMBC

BlackRock, Inc.
$81.0M9,167,212 sh
YACKTMAN ASSET MANAGEMENT LP
$32.5M3,671,877 sh
River Road Asset Management, LLC
$30.5M3,449,502 sh
AMERICAN CENTURY COMPANIES INC
$30.4M3,439,512 sh
VANGUARD CAPITAL MANAGEMENT LLC
$22.7M2,563,951 sh
STATE STREET CORP
$22.5M2,545,973 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$22.4M2,534,961 sh
LEUCADIA NATIONAL CORP
$20.8M2,355,162 sh
Sio Capital Management, LLC
$16.3M1,847,850 sh
MILLENNIUM MANAGEMENT LLC
$14.1M1,594,145 sh

Fund	Value	Shares
BlackRock, Inc.	$81.0M	9,167,212
YACKTMAN ASSET MANAGEMENT LP	$32.5M	3,671,877
River Road Asset Management, LLC	$30.5M	3,449,502
AMERICAN CENTURY COMPANIES INC	$30.4M	3,439,512
VANGUARD CAPITAL MANAGEMENT LLC	$22.7M	2,563,951
STATE STREET CORP	$22.5M	2,545,973
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$22.4M	2,534,961
LEUCADIA NATIONAL CORP	$20.8M	2,355,162
Sio Capital Management, LLC	$16.3M	1,847,850
MILLENNIUM MANAGEMENT LLC	$14.1M	1,594,145

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EMBC on your watchlist

Track score changes the day Embecta Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EMBC a good stock to buy?

13F Pro's AI-powered analysis of Embecta Corp. (EMBC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EMBC are available on the EMBC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EMBC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EMBC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Embecta Corp.'s investment landscape.